Lanadelumab reduces hae attack rate: interim findings from the help open-label extension study

Efficacy of lanadelumab in preventing hereditary angioedema (HAE) attacks was demonstrated in the double-blind, phase 3 HELP study (NCT02586805). This analysis reports interim data (26May2017-1September2017) on HAE attack rate with lanadelumab in the ongoing open-label extension (OLE) study (NCT02741596).

Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: M. Riedl, J. Bernstein, W. Yang, H. Longhurst, M. Magerl, J. Hebert, M. Shennak, I. Martinez-Saguer Tags: P168 Source Type: research